Top Small Cap Stocks To Watch Now – August 27th

ProShares UltraPro Short QQQ, AltC Acquisition, Spring Valley Acquisition, Hyperliquid Strategies, and Celularity are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations, typically ranking below large- and mid-cap companies in total market value. They may offer greater growth potential, but they often carry higher volatility, lower liquidity, and greater business risk than stocks of larger companies. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Spring Valley Acquisition (SV)

Hyperliquid Strategies (PURR)

Celularity (CELU)

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.